Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant (Immuno-POWER Trial): Big Ten Cancer Research Consortium BTCRC-MM19-428
Latest Information Update: 24 Aug 2021
At a glance
- Drugs Elotuzumab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms Immuno-POWER
- 18 Aug 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Jan 2021 Planned initiation date changed from 1 Dec 2020 to 1 Apr 2021.
- 13 Oct 2020 New trial record